Literature DB >> 11300606

Scavenger treatment of free radical injury in familial amyloidotic polyneuropathy: a study on Swedish transplanted and non-transplanted patients.

O B Suhr1, K Lång, L Wikström, I Anan, Y Ando, M El-Salhy, G Holmgren, K Tashima.   

Abstract

Since oxidative stress has been implicated in amyloid diseases, a study of scavenger treatment of hereditary transthyretin amyloidosis was undertaken on 23 familial amyloidotic polyneuropathy (FAP) patients. Nine patients had undergone a liver transplantation for the disease. Twenty patients completed the 6-month study period of scavenger treatment (vitamin C, 1 g, three times daily, vitamin E, 0.1 g, three times daily and acetylcysteine, 0.2 g three times daily). They were evaluated clinically and by immunohistochemical measurement of hydroxynonenal (HNE), a product of lipid peroxidation, in biopsy specimens. For non-transplanted patients, no improvement was found for HNE in relation to the amyloid content in biopsy specimens, whereas a tendency to a decreased amount was noted for transplanted patients. Clinically, no differences were found for non-transplanted patients, but an increased nutritional status, measured by a modified body mass index (mBMI) was noted for transplanted patients. In summary, scavenger treatment with the drugs and doses used in the present study appears to be unable to decrease lipid peroxidation in amyloid-rich tissue in non-transplanted FAP patients. For transplanted patients, lipid peroxidation tended to decrease, and the nutritional status measured by mBMI improved, even though the findings may be explained by liver transplantation alone, scavenger treatment may facilitate recovery after transplantation.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11300606     DOI: 10.1080/00365510151067884

Source DB:  PubMed          Journal:  Scand J Clin Lab Invest        ISSN: 0036-5513            Impact factor:   1.713


  5 in total

Review 1.  Liver transplantation and new therapeutic approaches for familial amyloidotic polyneuropathy (FAP).

Authors:  Yukio Ando
Journal:  Med Mol Morphol       Date:  2005-09       Impact factor: 2.309

Review 2.  Overview of treatments used in transthyretin-related hereditary amyloidosis: a systematic review.

Authors:  Héctor Cristóbal Gutiérrez; Ana Lara Pelayo-Negro; David Gómez Gómez; Miguel Ángel Martín Vega; Marta Valero Domínguez
Journal:  Eur J Hosp Pharm       Date:  2019-03-19

3.  Loss of gastric interstitial cells of Cajal in patients with hereditary transthyretin amyloidosis.

Authors:  Jonas Wixner; Konen Obayashi; Yukio Ando; Pontus Karling; Intissar Anan
Journal:  Amyloid       Date:  2013-05-03       Impact factor: 7.141

4.  Familial amyloidotic polyneuropathy: current and emerging treatment options for transthyretin-mediated amyloidosis.

Authors:  Ernst Hund
Journal:  Appl Clin Genet       Date:  2012-06-18

5.  Inhibition of TTR aggregation-induced cell death--a new role for serum amyloid P component.

Authors:  Karin Andersson; Malgorzata Pokrzywa; Ingrid Dacklin; Erik Lundgren
Journal:  PLoS One       Date:  2013-02-04       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.